CD274 and neoplasm: Therefore, treatment with pembrolizumab at a dose of 200 mg every 3 weeks was initiated as the first-line therapy for recurrent and metastatic hypopharyngeal cancer based on a combined positive score of 5 for PD-L1 in the tumor specimen obtained from the resected lung (9).